







Pathological Report









Foamy macrophages



Lymphocytes and plasma cells





fibrosis




Pathological Report



CD3







lgG4

CD68

Pathological Report



Mahidol University Faculty of Medicine Ramathibodi Hospital

Pituitary tissue biopsy

- Chronic hypophysitis with clusters of foamy macrophages
- Negative for malignancy or pituitary tissue
- IHC reveals
 - CD3 : positive in small lymphocytes
 - CD20 : positive in small lymphocytes
 - CD138 : positive in few plasma cells
 - CD68 : positive in multiple or cluster of foamy macrophages
 - IgG : positive in few plasma cells
 - IgG4 : negative

From histomorphology and IHC panel, **xanthomatous hypophysitis** is most likely




Diagnosis : Xanthomatous hypophysitis



Hypophysitis



Primary	Secondary		
(autoimmune or idiopathic)	AIH associated with	Autoimmune Polyglandular Syndrome, Autoimmune thyroid disease, Autoimmune adrenalitis, Type 1 diabetes mellitus	
Lymphocytic hypophysitis	other endocrinopathies		
Granulomatous hypophysitis	AIH associated with	Erdheim-Chester disease, Rheumatologic conditions (e.g.: sarcoidosis, Sjogren's,SLE), Vasculitides, Primary biliary cirrhosis, Atrophic gastritis, Optic neuritis, Myocarditis, IgG4-related disease, Langerhans cell histiocytosis, Rosai-Dorfman disease, Tolosa-Hunt syndrome, Cogan's syndrome, Thymoma (anti-Pit-1	
Xanthomatous hypophysitis	systemic diseases		
IgG-4 mediated (plasmacytic) hypophysitis			
Necrotizing hypophysitis			
Mixed forms (lymphogranulomatous; xanthogranulomatous)	AIH secondary to Drugs	antibody syndrome) Immune checkpoint inhibitors, Interferon-α , Ribavirin, Ustekinumab	
	AIH secondary to sellar and/or suprasellar lesions	Germinoma, Rathke's cleft cyst, Craniopharyngioma, Pituitary adenoma, Pituitary apoplexy, Pituitary hyperplasia,Primary pituitary lymphoma, Gliomas, Meningiomas,Pituicytomas, Chordomas, Teratomas, Dermoids ,Epidermoids	
	AIH secondary to infections	Tuberculosis, Syphilis, Viruses, Parasites, Abscesses	



J Clin Endocrinol Metab, Volume 107, Issue 1, January 2022,10-28



Summary of hypophysitis types, features and treatment options

Hypophysitis type	Etiology, demographics	Clinical presentation	Treatment, outcome
Lymphocytic Lymphocytic infiltration, plasma cells, histiocytes and fibrosis	Primary: F > M; F: 3 rd decade, pregnancy and peripartum; M: 4 th decade; co-existing autoimmunity Secondary: Found in sellar and suprasellar lesions (adenoma, craniopharyngioma, cyst, germinoma, lymphoma, <i>etc.</i>)	Deficiencies: Anterior hypopitutarism; DI is less frequent MRI: Enlarged homogeneously enhancing gland; stalk thickening. Empty sella in later stages Autoimmunity: thyroid disease, type 1 DM, celiac disease, connective tissue disorders, autoimmune GI disorders	Observation in mild-moderate cases GC in moderate-severe cases Immunosuppressants, surgery, radiation in GC-resistant cases Outcome is usually favorable
Granulomatous Multinucleated giant cells, histiocytes, lymphocytes, granulomas	Primary: Idiopathic F > M, 5 th decade Secondary: Isolated or part of systemic disease, <i>e.g.</i> sarcoidosis, GPA, tuberculosis, LCH/ECD	Deficiencies: Anterior hypopituitarism, frequent DI. More severe than lymphocytic type, frequent headache MRI: Enlarged gland; stalk thickening	GC less effective for idiopathic granulomatous hypophysitis Immunosuppressants, surgery, radiation for GC-resistant, LCH Chemotherapy (LCH, ECD) Outcome variable
Xanthomatous CD68 positive foamy macrophages, cholesterol clefts, hemosiderin deposits	F > M, 4 th decade Secondary to local processes; hemorrhage/rupture of Rathke cleft cyst, craniopharyngioma; also seen in systemic autoimmune disorders	Deficiencies: Anterior hypopituitarism, DI Frequent headache MRI: Cystic mass	Surgery is usually necessary Limited reponse to GC Outcome variable; complete recovery has been described

J Clin Endocrinol Metab, Volume 107, Issue 1, January 2022, 10–28



Summary of hypophysitis types, features and treatment options

Necrotizing Extensive necrosis, lymphocytes, plasmacytes, few eosinophils	Very rare, few cases described F > M, 2 nd -4 th decade Etiology unknown; possibly autoimmune	Deficiencies: Anterior hypopituitarism, DI MRI: Enlarged gland; stalk thickening; poor contrast enhancement; apoplexy-like appearance	Surgery for mass effect Role of GC and immunosuppressants unknown Pituitary deficiencies usually persist
IgG4-related ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	M > F, 5 th –7 th decade Secondary to IgG4 related disease but can be isolated	Deficiencies: Anterior hypopituitarism; DI very common MRI: Enlarged gland; stalk thickening Systemic IgG4 disease: retroperitonal fibrosis, pancreatitis, sialadenitis, polyadenopathy, Riedel thyroiditis; IgG4 levels variable	GC – usually excellent radiographic response to supraphysiologic doses Hypopituitarism may be permanent
Immunotherapy induced Diffuse infiltration with lymphocytes (left) and macrophages (right)	M > F, 6 th decade Ipilimumab: 8–10% (up to 17%) Tremelimumab: 0–2.6% Nivolumab: 0–3% Pembrolizumab: 0–5% Nivolumab + Ipilimumab: 8–13%	Deficiencies: Anterior hypopituitarism with predominant AI; rarely DI MRI: Enlarged gland (usually mild/moderate); stalk thickening	Replacement dose GC in mild-moderate cases High-dose GC and withdraw immunotherapy temporarily in severe cases Radiographic outcome favorable; pituitary deficiencies usually persistent
Other autoimmune Pathiology not well described; lymphocytic infiltration	Anti-PIT-1 hypophysitis – associated with thymoma Anti-POMC or anti-ACTH – associated with APS, ectopic POMC and ACTH expressing NETs Antibodies against pituitary cells have been implicated	Deficiencies: Anti-PIT-1 hypophysitis – GH, PRL, and TSH deficiency Anti-POMC or Anti-ACTH: Isolated ACTH deficiency Other isolated deficiencies MRI: usually normal or atrophic gland	Role of GC is unkown Treat underlying condition Pituitary deficiencies persist

J Clin Endocrinol Metab, Volume 107, Issue 1, January 2022, 10–28

Xanthomatous hypophysitis

- The rarest subtype of primary hypophysitis
- Only 37 cases from 1998-2022


Characteristic

Age : mean 39.1 years (range 12-72 years) Gender : 75% were female Symptoms

- Headache 68.6%
- Visual impairment 34.3%
- DI 36.1%
- Menstrual disorder in female 66.7%
- Fever 8.3%



Mahidol University Faculty of Medicine Ramathibodi Hospital



Xanthomatous hypophysitis


Pituitary hormone dysfunction

- Hypogonadotropic hypogonadism 63.6%
- Adrenocortical insufficiency 54.5%
- Central hypothyroidism 54.6%
- GH deficiency 63.6%
- Hyperprolactinemia 42.4%

MRI presentation

- Cystic mass with ring or peripheral enhancement
- Mean maximum diameter was 16.3 ± 4.8 mm.
- Pituitary stalk thickening : 50.0%






Gross presentation : cystic lesion with yellowish pus-like fluid **Pathological feature** : foamy histiocyte infiltration, which can be marked by **CD68** glycoprotein on immunohistochemistry



Xanthomatous hypophysitis

Treatment

- Lack of best evidence for treatment
 lack of follow up data
- Surgical resection should be considered, especially for patients suffering from mass effects and pituitary dysfunction
- \rightarrow total mass resection is recommended
- Close follow-up and routine assessment of pituitary function
- Hormone replacement therapy





Summary

- Xanthomatous hypophysitis is a rare entity of primary hypophysitis. Less than 40 cases have been reported until now.
- Patients could present with both anterior and posterior pituitary hormone dysfunction.
- Not all hypophysitis patients have stalk thickening
- Pituitary biopsy is usually considered either when a diagnosis is unclear.
- The pathological results show a presence of foamy macrophages and positive CD68
- There is no therapeutic cure. The main management is hormone replacement.